

Fig. 2

2/16







Fig. 3










Fig. 7




Fig. 8





Fig. 9

STUDY 002 RETROSLPENIAL CORTICAL ASTROCYTOSIS







Fig. 10








Fig. 12




Fig. 13




Fig. 14

PBS CONTROL		UNTREATED CONTROL	
624-165 625-166 626-167 633-168 634-169 671-170 672-171 829-172 830-173 831-174 792-175 793-176 794-177 732-178 733-179 734-180	272 1802 62 4696 3090 2417 2840 3320 1833 416 126 2559 289 179 1329 5665	764-181 785-182 766-183 767-184 768-185 771-186 772-187 780-188 843-189 844-190 845-191 846-192 887-193 888-194 889-195	3470 171 91 6692 1353 1153 3800 3740 163 122 427 2674 453 2996 1075
MEDIAN p MALUE (M-W)	1817	MEDIAN p MALUE (M-W)	1153
MEAN ST. DEV. % CV p VALUE (t TEST)	1931 1718 89 n=16	MEAN ST. DEV. % CV p VALUE (t TEST)	1825 1769 97 n=15

Fig. 15A

		•	
2 mg ALUM 100 μg AN1528		50 μg MPL 100 μg AN1528	
660-083 661-084 662-085 663-086 664-087 665-088 693-089 694-090 695-091 697-092 698-093 699-094 701-095 702-096 703-097 739-098 740-099 741-100 800-103 801-104	295 3180 2480 3014 5870 5978 1620 35 3400 2630 983 5327 1862 1849 2239 806 5303 459 154 852	643-105 644-106 645-107 654-108 655-109 656-110 678-111 679-112 704-114 705-115 706-116 729-117 730-118 731-119 736-120 737-121 757-122 758-123 808-124 809-125 810-126	385 2640 2403 1741 3053 5990 3360 1230 2680 78 1290 3180 1833 4590 1112 1653 992 4692 785 244 32
MEDIAN p MALUE (M-W)	2051	MEDIAN p MALUE (M-W)	1741
MEAN ST. DEV. % CV p VALUE (t TEST)	2407 1913 79 n=20	MEAN ST. DEV. % CV p VALUE (t TEST)	2140 1659 78 n=21

Fig. 15B

25 μg QS21 100 μg AN1528		CEA/IFA 100 µg AN1792		
615-128 616-129 617-130 536-131 637-132 638-133 744-134 745-135 746-136 747-137 769-138 770-139 773-140 774-141 775-142 776-143 840-144 841-145 821-146 823-148	1257 361 1008 3290 2520 3880 627 58 2610 1509 1788 988 1199 339 402 537 1119 194 1259 5413 2233	539-068 640-069 641-070 642-071 690-072 691-073 692-074 795-075 796-076 797-077 748-087 749-079 750-080 751-081 761-082	693 508 440 467 42 2491 121 137 822 475 600 78 1267 1351 69	
MEDIAN p MALUE (M-W)	1199	MEDIAN p MALUE (M-W)	475 0.0481	
MEAN ST. DEV. % CV p VALUE (t TEST)	1552 1364 88 n=21	MEAN ST. DEV. % CV p VALUE (t TEST)	637 655 103 0.0106 n≂15	

Fig. 15C



		MILA	
5 μg THIMEROSAL/PBS 10 μg AN1792		2 μg ALUM 100 μg AN1792	
635-149 669-150 670-151 673-152 674-153 676-154 681-156 682-157 683-158 754-159 755-160 756-161 805-162 806-163 807-164	1337 4644 6335 3700 2750 1687 185 8031 3450 157 6857 482 524 397 234	610-001 611-002 612-003 613-004 620-005 621-006 622-007 623-008 708-009 709-010 710-011 716-012 784-014 785-015 786-018 787-017 788-018 789-019 815-020 816-021 817-022	432 1012 3607 508 465 16 28 217 2738 927 1609 1608 3890 1614 285 3102 1617 1474 424 1375 2323
MEDIAN p MALUE (M–W)	1687	MEDIAN p MALUE (M–W)	1375 0.5000
MEAN ST. DEV. % CV P VALUE (t TEST)	2718 2685 99 n=15	MEAN ST. DEV. % CV p VALUE (t TEST)	1394 1166 84 0.2650 n=21

Fig. 15D

50 μg MPL		25 μg QS21	
100 μg AN1792		100 μg AN1792	
646-023 647-024 648-025 649-026 650-027 724-028 726-030 727-031 720-032 721-033 802-034 803-035 804-036 811-037 812-038 813-039 814-040 833-014 834-042	2002 147 1304 34 980 1282 1966 733 2563 5563 113 671 51 613 332 1454 2441 742 40 807	627-045 628-046 631-049 632-050 667-052 668-053 686-054 687-055 688-056 689-057 712-059 825-061 826-082 827-063 828-064 837-065 838-066	91 3397 3702 1776 1832 3023 189 891 240 110 3311 1009 18165 73 78 1051 270
MEDIAN	774	MEDIAN	950
p MALUE (M-W)	0. 1710	p MALUE (M-W)	0.4076
MEAN ST. DEV. % CV p VALUE (t TEST)	1192 1299 109 0.1506 n=21	MEAN ST. DEV. % CV p VALUE (t TEST)	2199 4187 190 0.8131 n=18

Fig. 15E

Mean Titer of Mice Treated with Polyclonal Anti AB Antibody




Fig. 16




Fig. 17

3 - 3

Mean Titer of Mice Treated with Monoclonal 21F12 Anti-Abeta Antibody




Fig. 18